Nasally delivered SARS-CoV-2 vaccines: future promise and challenges.
Shaw RH., (2023), Lancet Respir Med, 11, 1038 - 1039
Heat inactivation of clinical COVID-19 samples on an industrial scale for low risk and efficient high-throughput qRT-PCR diagnostic testing
Delpuech O. et al, (2022), Scientific Reports, 12
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M. et al, (2021), Lancet, 397, 881 - 891
Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum
Dejnirattisai W. et al, (2021)
Improving Robustness of Pharmaceutical Dosage form Sample Preparation Using Experimental Design and Process Understanding Tools
Ferguson PD. et al, (2020), Chromatographia, 83, 1525 - 1538
Identification of pharmacodynamic transcript biomarkers in response to FGFR inhibition by AZD4547
Delpuech O. et al, (2016), Molecular Cancer Therapeutics, 15, 2802 - 2813
Overcoming Obstacles in the Implementation of Factorial Design for Assay Optimization
Shaw R. et al, (2015), Assay and Drug Development Technologies, 13, 88 - 93
Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib
Pommier AJC. et al, (2014), British Journal of Cancer, 111, 1590 - 1604
Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies
Farren M. et al, (2012), Angiogenesis, 15, 555 - 568
Reduction in laboratory animal use by factorial design
Shaw R., (2004), ATLA Alternatives to Laboratory Animals, 32, 49 - 51
Use of factorial designs to optimize animal experiments and reduce animal use
Shaw R. et al, (2002), ILAR Journal, 43, 223 - 232